Which generation of targeted drug is dacomitinib/dacomitinib?

Dacomitinib/Dacomitinib is a second-generation targeted drug. Dacomitinib is a drug used to treat EGFRExon19Deleted exon21 L858RReplacement drug for non-small cell lung cancer.

Preclinical data indicate that dacomitinib/dacomitin increases the inhibitory effect of the epidermal growth factor receptor kinase domain and the activity of cell lines containing resistance mutations such as T790M. This activity further significantly reduced EGFR phosphorylation and cell viability. In these studies, using a non-small cell lymphoma cancer cell line harboring the L858R/T790M mutation, the observed IC50 was approximately 280 nmol/L.

In a clinical trial of patients with advanced non-small cell lung cancer who progressed after chemotherapy, the objective response rate was 5%, progression-free survival was 2.8 months, and overall survival was 9.5 months. In addition, a phase I/II study showed positive activity of dakotinib despite previous failure of tyrosine kinase inhibitors. A phase III clinical trial (ARCHER 1050) in patients with advanced or metastatic non-small cell lung cancer with EGFR activating mutations reported a significant improvement in progression-free survival compared with gefitinib. If you want to get more high-quality information, you can contact Yaode, and Yaode will do its best to learn more about high-quality overseas drugs for you.